Clinically proven Repeated Low-Level Red-Light (RLRL) therapy device for controlling myopia progression in children. Non-invasive, at-home treatment with up to 87.7% efficacy.
Must be prescribed by an eye care professional
Efficacy when >75% compliant
Reduction in myopia progression
The EyeRising device delivers repeated low-level red-light therapy to the back of the eye, where it stimulates blood flow and thickens the layer of the back of the eye known as the choroid. This helps to slow further elongation of the eye's axial length and thereby control myopia progression.
The treatment enhances blood circulation in the ocular fundus, addressing sclera hypoxia and managing the axial elongation associated with myopia. Clinical trials demonstrate that higher treatment compliance leads to higher treatment effect.
As the device is non-invasive and has a wide age range availability, it offers an opportunity to start treatment earlier and in children who are not willing to use or compliant with eye drops or contact lenses.
Regulatory Approvals
Approved in over 30 countries including Australia (TGA), EU (CE), UK (MHRA), and New Zealand
Safety Standards
Complies with Australian Standard IEC 60825-1:2014 for laser products safety
Side Effects
Most common side effect is temporary afterimage that typically disappears within minutes
